Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype — Stella

Home/Opioid Withdrawal/Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

View on ClinicalTrials.gov

Recruiting

Back to Opioid Withdrawal trials

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

University of Maryland, Baltimore, Maryland

Key details

Phase

Safety & dosing

Sponsor

University of Maryland, Baltimore

Collaborators

National Institute on Drug Abuse (NIDA)

Enrollment target

~60 participants

Started

December 2021

Primary completion

November 2026

Age range

18 Years – 65 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.